(Q41174885)

27 September 2017

1 reference

title

Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis (English)

1 reference

27 September 2017

0 references

Perez EA

1

1 reference

27 September 2017

publication date

1 July 1996

1 reference

27 September 2017

published in

Clinical Therapeutics

1 reference

27 September 2017

volume

18

1 reference

27 September 2017

issue

4

1 reference

27 September 2017

page(s)

578-90; discussion 577

1 reference

Potential for combination therapy with the new antiserotonergic agents

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Clinical evaluation of 5-HT3 receptor antagonists as anti-emetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

New directions for anti-emetic research.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Methodology of antiemetic trials: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Oral granisetron--simple and effective: a preliminary report. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Controlling emesis related to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

Tropisetron. A review of the clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980209-8

7 January 2021

10.1016/S0149-2918(96)80209-8

Identifiers

DOI

1 reference

27 September 2017

1 reference